In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Eisai Sets Domestic Sales Forecast for Aricept at 90 Billion Yen on Impact of Generics
May 17, 2012
-
BUSINESS Top Five Drug Makers Report 12.8% Decline in Operating Profits with 3 Reporting Double-Digit Falls in Profits
May 17, 2012
-
BUSINESS Pivotal Focus for Biosimilars Business on Japan: Daiichi Sankyo President Nakayama
May 16, 2012
-
BUSINESS Operating Profit Ratio for Pharmaceutical Wholesales at 0.32%, Improved but Still in Low Range: Top 4 Wholesalers
May 15, 2012
-
BUSINESS Midterm Plan to Overcome Generic Versions of Actos, Setting Sights on Emerging Markets: Takeda
May 15, 2012
-
REGULATORY Gov’t to Begin Operating “Drug Discovery Network” This FY with Initial Focus on Seeds for Anticancer Agents
May 14, 2012
-
BUSINESS The Growing Presence of Foreign-Affiliates (2)
May 14, 2012
-
BUSINESS “Figures to Look Forward to in 2013-2014” in Firm US Operations: President Teshirogi of Shionogi
May 11, 2012
-
BUSINESS Tenelia Planned to “Overwhelm Market with Power” in Alliance with Daiichi Sankyo: MTPC
May 10, 2012
-
ORGANIZATION Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
-
BUSINESS Daiichi Sankyo Ties Up with Coherus BioSciences to Embark on Biosimilars Business
May 9, 2012
-
BUSINESS OrphanPacific Focuses on Building Detailing Form: President Ichikawa
May 8, 2012
-
BUSINESS DSP Aims to Enhance Its Presence in Field of Oncology by Developing First-in-Class Drugs
May 7, 2012
-
ACADEMIA St. Marianna University School of Medicine Hospital to Introduce CDTM, Protocols for Pharmacists to Determine Prescriptions
April 27, 2012
-
REGULATORY CSIMC to Establish Expert Subcommittee on Cost-Effective Assessments, 1st Meeting Scheduled in June
April 26, 2012
-
BUSINESS Generics Aimed for Early Stage Sales of 10 Billion Yen, in the Black for Establishing Base: Daiichi Sankyo Espha President Yoshiwaka
April 25, 2012
-
BUSINESS Astellas Senior VP Sato Shares Plans to Market Gonax Within Current Structure, MRs Dedicated to Cancer “a Future Issue”
April 24, 2012
-
BUSINESS Daiichi Sankyo Looking to Establish “Base Treatment” Position for Memary
April 23, 2012
-
ORGANIZATION JPMA Opposes Haste Adoption of Cost-Effective HTA
April 20, 2012
-
BUSINESS Takeda to Differentiate New ARB Azilva Stressing Its Strong Hypotensive Effects
April 19, 2012
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…